In this issue:
Real-world outcomes for osimertinib-/platinum-resistant EGFR-mutated NSCLC
Camrelizumab + platinum chemotherapy in resectable stage IIIA–IIIB NSCLC
Datopotamab deruxtecan (an ADC) in NSCLC
Adagrasib in KRAS G12C-mutated NSCLC with CNS metastases
Atezolizumab + carboplatinpemetrexed for advanced nonsquamous NSCLC with brain metastases
Pralsetinib for advanced RET-fusion-positive NSCLC
Postchemotherapy adjuvant atezolizumab in resected stage II–IIIA NSCLC
Cancer vaccine in immunotherapy-resistant HLA-A2-positive advanced NSCLC
First-line nivolumab + ipilimumab in metastatic NSCLC
Reducing chemoimmunotherapy dose in lung squamous cell carcinoma
Please login below to download this issue (PDF)